ESTUTC-5 New YorkLog in Sign up

QURE
uniQure N.V.
stockNASDAQ

At CloseNov 6, 2026 3:59:54 PM EST

21.69USD+3.237%(+0.68)1,172,907

Pre-marketNov 6, 2026 9:27:30 AM EST

21.21USD+0.952%(+0.20)

After-hoursNov 6, 2026 4:57:30 PM EST

20.83USD-3.947%(-0.86)

QURE News

Day breaks

12:11 AM ESTQURE SWOT Analysis: Financial Struggles Amid Promising Gene Therapy Pipeline Revealed in 10-Q Filing ·

GuruFocus

04:11 PM ESTuniQure NV (QURE) (Q3 2026) Earnings Call Highlights: FDA Priority Review for AMT-130 and a ... ·

GuruFocus

03:01 PM ESTQ3 2026 uniQure N.V. Earnings Call Transcript ·

GuruFocus

02:25 PM ESTuniQure (QURE) Q3 2026 Earnings Call Transcript ·

The Motley Fool+1 source

02:05 PM ESTUniQure outlines AMT-130 confirmatory study of ~200 patients with May 1, 2027 PDUFA date in focus ·

Seeking Alpha

02:04 PM ESTuniQure N.V. (QURE) Q3 2026 Earnings Call Transcript ·

Seeking Alpha

07:33 AM ESTuniQure NV Reports Q3 2026 Results: GAAP EPS Loss of $0.88 Misses Estimates; Revenue of $5. ... ·

GuruFocus

07:10 AM ESTuniQure GAAP EPS of -$0.88 beats by $0.01, revenue of $5.2M misses by $0.85M ·

Seeking Alpha

07:05 AM ESTuniQure Announces Third Quarter 2026 Financial Results and Provides Company Update ·

GlobeNewswire Inc.

11:06 AM ESTuniQure Q3 2026 Earnings Preview ·

Seeking Alpha

12:56 PM ESTuniQure's Gene Therapy BLA for Huntington's Disease Gains FDA Priority Review (QURE) ·

GuruFocus

11:54 AM ESTuniQure gains FDA Priority Review for Huntington's disease gene therapy ·

Seeking Alpha

07:51 AM ESTFDA Accepts uniQure's BLA for Huntington's Gene Therapy, Ticker QURE Sees Mixed Signals ·

GuruFocus

07:05 AM ESTuniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease ·

GlobeNewswire Inc.

07:05 AM EDTuniQure to Announce Third Quarter 2026 Financial Results ·

GlobeNewswire Inc.

09:20 AM EDTCedar Grove Capital Q3: Adds Zedcor, Auxly; exits MTY, ClearPoint ·

Seeking Alpha

07:11 PM EDTuniQure N.V. Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your QURE Investments ·

Newsfile

06:00 PM EDTUNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 37.3% Share Drop ·

Business Wire

11:01 AM EDTThis week’s top stock pitches from investment newsletters. ·

Stock Analysis Compilation